Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

25.7%

9 terminated/withdrawn out of 35 trials

Success Rate

65.4%

-21.1% vs industry average

Late-Stage Pipeline

11%

4 trials in Phase 3/4

Results Transparency

59%

10 of 17 completed trials have results

Key Signals

2 recruiting10 with results8 terminated

Enrollment Performance

Analytics

Phase 2

15(44.1%)

Phase 1

13(38.2%)

Phase 3

4(11.8%)

Early Phase 1

1(2.9%)

N/A

1(2.9%)

34Total

Phase 2(15)

Phase 1(13)

Phase 3(4)

Early Phase 1(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (35)

Showing 20 of 35 trials

NCT05665166Phase 1Active Not Recruiting

Gene Therapy With Modified Autologous Hematopoietic Stem Cells for Patients With Mucopolysaccharidosis Type II

Role: collaborator

NCT06343792Phase 2Recruiting

Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease

Role: collaborator

NCT03183245Phase 3Completed

Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis

Role: collaborator

NCT02836574Phase 2Completed

A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease

Role: collaborator

NCT02644941Phase 3Completed

Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis

Role: collaborator

NCT04201405Phase 1Active Not Recruiting

Gene Therapy with Modified Autologous Hematopoietic Stem Cells for Patients with Mucopolysaccharidosis Type IIIA

Role: collaborator

NCT03270956Phase 2Completed

A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease

Role: collaborator

NCT05291286Early Phase 1Completed

BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients

Role: collaborator

NCT04771897Phase 1Terminated

A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)

Role: collaborator

NCT04404569Phase 1Terminated

Continued Treatment for Participants Enrolled in Studies of BXQ-350

Role: collaborator

NCT05322590Phase 1Active Not Recruiting

BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma

Role: collaborator

NCT03621605Phase 1Terminated

A Phase1 Study of VIB9600

Role: collaborator

NCT03432260Phase 2Completed

A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis

Role: collaborator

NCT04563026Phase 2Completed

A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment

Role: collaborator

NCT04137900Phase 1Recruiting

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

Role: collaborator

NCT04115345Phase 1Completed

A Study of a Renal Autologous Cell Therapy (REACT) in Patients With Chronic Kidney Disease (CKD) From Congenital Anomalies of the Kidney and Urinary Tract (CAKUT).

Role: collaborator

NCT04540120Phase 2Terminated

Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome

Role: collaborator

NCT00323037Phase 3Completed

A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure

Role: collaborator

NCT03347708Phase 1Completed

Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration

Role: collaborator

NCT05253105Phase 1Withdrawn

A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies

Role: collaborator